PLUVICTO

Peak

lutetium lu 177 vipivotide tetraxetan

Novartis
NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3

Mechanism of Action

Radioligand Activity

Pharmacologic Class:

Radioligand Therapeutic Agent

Clinical Trials (3)

NCT06514521N/ARecruiting

Post Marketing Study on Pluvicto in Korea

Started Apr 2025
278 enrolled
Metastatic Castration-resistant Prostate Cancer
NCT06516510Phase 1Terminated

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Started Oct 2024
17 enrolled
Metastatic Prostate Cancer
NCT05682443Phase 1/2Active Not Recruiting

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Started Dec 2023

Loss of Exclusivity

LOE Date
Sep 18, 2041
189 months away
Patent Expiry
Sep 18, 2041
Exclusivity Expiry
Mar 28, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10406240
Aug 15, 2028
SubstanceProduct
U-4169
11318121
Aug 15, 2028
SubstanceProduct
U-4169
10398791
Oct 17, 2034
SubstanceProduct
—
11951190
Nov 12, 2035
U-4169
12208102
Sep 18, 2041
U-4169
Company
Novartis
Novartis
BASEL, Switzerland
646 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers